Alkaline Phosphatase for treatment of Ulcerative Colitis (805 KB)
There appears to be a strong link between presence of high levels of LPS in the colon and the occurrence of Inflammatory Bowel Disease. AM-Pharma is developing a unique therapy against IBD, based on dephosphorylation and thus detoxification of the bacterial endotoxin LPS by Alkaline Phosphatase (AP).
Results from phase I and II clinical trials where AP was delivered through a duodenal drip have confirmed the safety of AP as an oral therapy for Ulcerative Colitis (UC).
An open label patient trial has been performed in 21 moderate to severe UC patients refractory to steroids and immune suppressants. The results of this trial indicate that these patients benefit significantly from the treatment with AP.
|
|
Alkaline Phosphatase for treatment of Ulcerative Colitis (805 KB) |